½ºÅ¸°¡¸£Æ®º´ Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, ¿¬·ÉÃþº°, À¯Åë ä³Îº°, Áö¿ªº°
Stargardt Disease Therapeuticss Market, By Drug Type (Emixustat, LBS-008, others, By Age Group (Children and Adult ), By Distribution Channel, and By Region
»óǰÄÚµå : 1357962
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2023³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,197,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,640,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,772,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½ºÅ¸°¡¸£Æ®º´ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 2¾ï 1,350¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£(2023-2030³â) CAGRÀº 31.7%·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ´ë»ó ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2022³â 2023³â ½ÃÀå ±Ô¸ð 2¾ï 1,350¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030
¿¹Ãø ±â°£ CAGR 31.70% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 14¾ï 6,720¸¸ ´Þ·¯
¼¼°èÀÇ ½ºÅ¸°¡¸£Æ®º´ Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²(%), ¾àÁ¦ À¯Çüº°, 2023³â
Stargardt Disease Therapeuticss Market-IMG1

½ºÅ¸°¡¸£Æ®º´Àº ´ÜÀÏ À¯ÀüÀÚÀÇ ¹Ì¼¼ÇÑ º¯È­·Î ÀÎÇØ ¹ß»ýÇÏ´Â À¯Àüº´ÀÔ´Ï´Ù. Çöóºñ¸¶Äí¶ó ¾ÈÀú¶ó°íµµ ºÒ¸®¸ç, Ȳ¹Ýº¯¼ºÀÇ °¡Àå ÈçÇÑ ÇüÅÂÀÔ´Ï´Ù. ¾à 1¸¸ ¸í Áß 1¸í²Ã·Î ¹ß»ýÇϸç, ³²³à ¸ðµÎ¿¡°Ô ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ½ºÅ¸°¥Æ®º´Àº Ȳ¹ÝÀ̶ó´Â ¸Á¸·ÀÇ Á߽ɺÎÀΠȲ¹ÝÀÇ ¼èÅ𸦠ÀÏÀ¸Åµ´Ï´Ù. ÀÌ ºÎºÐÀº °á±¹ Èò»ö ¶Ç´Â ³ë¶õ»öÀÇ ¹ÝÁ¡À¸·Î µÑ·¯½Î¿© ÀÖ½À´Ï´Ù. ¸Á¸·ÀÇ Áß¿äÇÑ ÃþÀÎ ¸Á¸·»ö¼Ò»óÇÇ(RPE)µµ ¸®Æ÷ǪƾÀ̶ó´Â '³ëÆó¹°'ÀÇ ÃàÀû¿¡ ÀÇÇØ ¿µÇâÀ» ¹Þ½À´Ï´Ù. ½ºÅ¸°¡¸£Æ®º´ Áø´ÜÀ» ¹Þ´Â °ÍÀº °íÅ뽺·¯¿î ÀÏÀÌÁö¸¸, ÀûÀýÇÑ Á¤º¸¿Í Áö¿øÀ» ¹ÞÀ¸¸é Àß ±Øº¹ÇÒ ¼ö ÀÖ½À´Ï´Ù. ´ëºÎºÐÀÇ °æ¿ì, ½ºÅ¸°¡¸£Æ®º´ ȯÀÚ°¡ ½Ã·ÂÀ» ¸ðµÎ ÀÒ´Â °ÍÀº ¾Æ´Ï¶ó´Â Á¡À» ±â¾ïÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. ½ºÅ¸°¡¸£Æ®º´Àº º¸Åë Á߽ɽ÷¿¡¸¸ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÁÖº¯ ½Ã·ÂÀº ÀϹÝÀûÀ¸·Î ¿µÇâÀ»¹ÞÁö ¾Ê½À´Ï´Ù. °¡´ÉÇÑ Ä¡·á¹ý¿¡ ´ëÇØ ¸¹Àº ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Ã·´Ü Ä¡·á¹ýÀÇ µµÀÔÀº ¿¹Ãø ±â°£ Áß ¼¼°è ½ºÅ¸°¡¸£Æ®º´ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ

ÀÇ·á±â±â »ê¾÷ÀÇ ÁÖ¿ä ¾÷üµéÀº ½ºÅ¸°¡¸£Æ®º´À» ¾Î°í ÀÖ´Â ´Ù¾çÇÑ È¯ÀÚ Ç®À» À§ÇÑ Ä¡·áÁ¦ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Ã·´Ü ¾à¹° ½ÃÀå µµÀÔÀº ¿¹Ãø ±â°£ Áß ¼¼°è ½ºÅ¸°¡¸£Æ®º´ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 6¿ù 5ÀÏ ¹ÙÀÌ¿À Á¦¾à»ç ¾ËŰ¿ì½º ÆÄ¸¶½´Æ¼Äýº´Â ¼Ò¾Æ ¹× ÀþÀº ¼ºÀÎ ½Ç¸íÀÇ ÁÖ¿ä À¯ÀüÀû ¿øÀÎÀÎ ½ºÅ¸°¡¸£Æ®º´ Ä¡·á¸¦ À§ÇØ Áúº´ º¯Çü °¡´É¼ºÀÌ ÀÖ´Â Á¤¹ÐÀÇ·áÀÎ Áö¸£µ¥¿ì·¹Æ¼³î(ALK-001)ÀÇ µî·Ï ¹× Ãâ½Ã¸¦ Áö¿øÇϱâ À§ÇØ À§ÇÑ ½Ã¸®Áî B ÆÝµùÀ¸·Î 1¾ï 5,000¸¸ ´Þ·¯¸¦ Á¶´ÞÇß´Ù°í ¹àÇû½À´Ï´Ù. À̹ø ÆÝµùÀº º£ÀÎijÇÇÅÐ »ý¸í°úÇа¡ ÁÖµµÇßÀ¸¸ç, TCGX, À£¸µÅÏ ¸Å´ÏÁö¸ÕÆ®, ¼ÒÇdzë¹Ù Àκ£½ºÆ®¸ÕÆ®°¡ Ãß°¡·Î Âü¿©Çß½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ½ºÅ¸°¡¸£Æ®º´ Ä¡·áÁ¦ ½ÃÀå - ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ ½ºÅ¸°¡¸£Æ®º´ Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, 2018-2030³â

Á¦6Àå ¼¼°èÀÇ ½ºÅ¸°¡¸£Æ®º´ Ä¡·áÁ¦ ½ÃÀå : ¿¬·ÉÃþº°, 2018-2030³â

Á¦7Àå ¼¼°èÀÇ ½ºÅ¸°¡¸£Æ®º´ Ä¡·áÁ¦ ½ÃÀå : À¯Åë ä³Îº°, 2018-2030³â

Á¦8Àå ¼¼°èÀÇ ½ºÅ¸°¡¸£Æ®º´ Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°, 2018-2030³â

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¼½¼Ç

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global stargardt disease therapeutics market is estimated to be valued at US$ 213.5 Mn in 2023, and is expected to exhibit a CAGR of 31.7% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 213.5 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 31.70% 2030 Value Projection: US$ 1,467.2 Mn
Global Stargardt Disease Therapeutics Market Share (%), By Drug Type, 2023
Stargardt Disease Therapeuticss Market - IMG1

Stargardt disease is a genetic condition that is caused by a tiny alteration in a single gene. It is also known as fundus flavimaculatus, and is the most common form of macular dystrophy. It affects approximately one in 10,000 people and affects both males and females. Stargardt causes a wasting of a central area of the retina called the macula. This area is eventually surrounded by a ring of white or yellow spots. An important layer of the retina, the retinal pigment epithelium (RPE), is also affected by an accumulation of 'waste' material called lipofuscin. Being diagnosed with Stargardt disease can be distressing, but with the right information and support, people can cope very well. It is important to remember that in the vast majority of cases, patients with stargardt disease do not lose all their sight. Stargardt disease usually affects central vision only. Peripheral vision is not usually affected. There is a great deal of research going on into potential treatments. Thus, introduction of such advanced treatment options in the market is expected to drive global stargardt disease therapeutics market growth over the forecast period.

Market Dynamics

The key players in the medical devices industry are focusing on the development of therapeutic drugs for various patient pool suffering from Stargardt disease. Thus, introduction of such advanced drugs in the market is expected to drive growth of the global stargardt disease therapeuticss market over the forecast period. For instance, on June 05, 2023, Alkeus Pharmaceuticals, a biopharmaceutical company, announced that the company had raised a US$ 150 million in Series B financing to support the registration and launch of gildeuretinol (ALK-001), a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a leading genetic cause of blindness in children and young adults. The financing was led by Bain Capital Life Sciences, with additional participation by TCGX, Wellington Management and Sofinnova Investments.

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Stargardt Disease Therapeutics Market - COVID-19 Impact Analysis

5. Global Stargardt Disease Therapeutics Market, By Drug Type, 2018-2030, (US$ Mn)

6. Global Stargardt Disease Therapeutics Market, By Age Group, 2018-2030, (US$ Mn)

7. Global Stargardt Disease Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Mn)

8. Global Stargardt Disease Therapeutics Market, By Region, 2018-2030, (US$ Mn)

9. Competitive Landscape

10. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â